Research programme: microRNA therapeutics - Regulus Therapeutics
Alternative Names: anti-miR-10b; anti-miR-122; anti-miR-132; miR-122; miR-296; miR-34; miR-34a; miR-K12-11 (viral oncomir); miR-X; miRNA therapeutics - Regulus Therapeutics; RGLS 5579; RGLS 6650; Viral microRNAs - Regulus TherapeuticsLatest Information Update: 28 Jun 2023
At a glance
- Originator California Institute of Technology/CalTech; Stanford University
- Developer Brigham and Women's Hospital; Cenix BioScience; Regulus Therapeutics
- Class Anti-infectives; Antihyperglycaemics; Antineoplastics; Antisense oligonucleotides; Antivirals; Cardiovascular therapies; Heart failure therapies; Hepatoprotectants; MicroRNAs
- Mechanism of Action MicroRNA inhibitors; MicroRNA modulators; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Non-alcoholic steatohepatitis
Highest Development Phases
- Preclinical Amyotrophic lateral sclerosis
- No development reported Glioblastoma; Hepatitis B; Hepatitis C; Immunological disorders; Infections; Non-alcoholic steatohepatitis
- Discontinued Diabetes mellitus; Heart failure; Metabolic syndrome; Viral infections
Most Recent Events
- 28 Jun 2023 No recent reports of development identified for preclinical development in Hepatitis-C in USA
- 28 Feb 2023 No recent reports of development identified for preclinical development in Immunological-disorders in USA
- 28 Feb 2023 No recent reports of development identified for preclinical development in Infections in USA